NO20092278L - Mikroorganismer som baerere av nukleotid sekvenser kodende for antigener og protein toksiner, fremgangsmate for fremstilling og anvendelser derav - Google Patents
Mikroorganismer som baerere av nukleotid sekvenser kodende for antigener og protein toksiner, fremgangsmate for fremstilling og anvendelser deravInfo
- Publication number
- NO20092278L NO20092278L NO20092278A NO20092278A NO20092278L NO 20092278 L NO20092278 L NO 20092278L NO 20092278 A NO20092278 A NO 20092278A NO 20092278 A NO20092278 A NO 20092278A NO 20092278 L NO20092278 L NO 20092278L
- Authority
- NO
- Norway
- Prior art keywords
- microorganism
- component
- specific
- nucleotide sequence
- expression
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title abstract 7
- 231100000654 protein toxin Toxicity 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 108700012359 toxins Proteins 0.000 title abstract 2
- 239000000969 carrier Substances 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 5
- 125000003729 nucleotide group Chemical group 0.000 abstract 5
- 230000004913 activation Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 230000028327 secretion Effects 0.000 abstract 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 210000000172 cytosol Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000002934 lysing effect Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
Abstract
Oppfinnelsen angår en mikroorganisme som en bærer av nukleotidsekvenser som koder for antigener og protein toksiner som innbefatter følgende komponenter: (I) minst en nukleotidsekvens som koder for minst ett fullstendig eller delvis antigen til minst ett villtype eller mutert protein; og (II) minst en nukleotidsekvens som koder for minst ett protein toksin og/eller minst en protein toksin underenhet; og (III) a) minst en nukleotidsekvens som koder for minst et transport system som muliggjør ekspresjonen av ekspresjonsproduktene til komponent (I) og komponent (II) på den ytre overflaten til mikroorganismen og/eller muliggjør sekresjonen av ekspresjonsproduktene til komponent (I) og komponent (II); og/eller som koder for minst en signalsekvens som muliggjør sekresjonen av ekspresjonsproduktene til komponent (I) og komponent (II); og/eller (III) b) eventuelt, minst en nukleotidsekvens som koder for minst ett protein for lysering av mikroorganismen i cytosolen til pattedyrceller og for intracellulært frigivende plasmider eller ekspresjonsvektorer, som er innbefattet i den lyserte mikroorganismen; og (IV) minst en nukleotidsekvens for minst en aktiveringssekvens for ekspresjonen av en eller flere av komponentene (I) til (III), hvori nevnte aktiveringssekvens kan bli aktivert i mikroorganismen og/eller er vevscelle spesifikk, tumorcelle spesifikk, makrofag spesifikk, dendritt spesifikk, lymfocytt spesifikk, funksjonsspesifikk eller ikke-celle spesifikk"; hvori en hvilken som helst av komponentene (I) til (IV) kan være tilstede enten en eller flere ganger og identiske eller forskjellige. Også beskrevet er en fremgangsmåte for fremstilling derav, korresponderende plasmider eller ekspresjonsvektorer og anvendelser av mikroorganismen som et medikament.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86548406P | 2006-11-13 | 2006-11-13 | |
EP06123974A EP1921149A1 (en) | 2006-11-13 | 2006-11-13 | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
US93914007P | 2007-05-21 | 2007-05-21 | |
PCT/EP2007/062237 WO2008058944A1 (en) | 2006-11-13 | 2007-11-13 | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20092278L true NO20092278L (no) | 2009-08-13 |
Family
ID=37846081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092278A NO20092278L (no) | 2006-11-13 | 2009-06-12 | Mikroorganismer som baerere av nukleotid sekvenser kodende for antigener og protein toksiner, fremgangsmate for fremstilling og anvendelser derav |
Country Status (30)
Country | Link |
---|---|
US (1) | US8669091B2 (no) |
EP (2) | EP1921149A1 (no) |
JP (1) | JP5479102B2 (no) |
KR (1) | KR101505413B1 (no) |
CN (1) | CN101595219B (no) |
AR (1) | AR063795A1 (no) |
AT (1) | ATE469971T1 (no) |
AU (1) | AU2007321266B2 (no) |
BR (1) | BRPI0719003A2 (no) |
CA (1) | CA2669219A1 (no) |
CY (1) | CY1111035T1 (no) |
DE (1) | DE602007006985D1 (no) |
DK (1) | DK2092067T3 (no) |
ES (1) | ES2347019T3 (no) |
HK (1) | HK1138314A1 (no) |
HR (1) | HRP20100466T1 (no) |
IL (1) | IL198736A0 (no) |
ME (1) | ME01846B (no) |
MX (1) | MX2009005038A (no) |
NO (1) | NO20092278L (no) |
NZ (1) | NZ576947A (no) |
PL (1) | PL2092067T3 (no) |
PT (1) | PT2092067E (no) |
RS (1) | RS51416B (no) |
RU (1) | RU2447145C2 (no) |
SI (1) | SI2092067T1 (no) |
TW (1) | TWI394834B (no) |
UA (1) | UA94974C2 (no) |
WO (1) | WO2008058944A1 (no) |
ZA (1) | ZA200903022B (no) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2331271B1 (es) * | 2007-06-29 | 2010-10-14 | Universidad Del Pais Vasco | Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas. |
WO2009094006A2 (en) * | 2007-10-25 | 2009-07-30 | Wake Forest University Health Sciences | Bordetella outer-membrane protein antigens and methods of making and using the same |
US20090208461A1 (en) * | 2008-02-05 | 2009-08-20 | Zentaris Gmbh | Recombinant bacteria with e.coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof |
CA2733425A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
KR101104077B1 (ko) * | 2008-10-14 | 2012-01-11 | 건국대학교 산학협력단 | Egr-1의 발현을 증가시키는 활성을 갖는 신규한 엔터로박테리아속에 속하는 신규균주 및 그 균주를 포함하는 조성물의 항암제로서의 용도 |
CN101480489B (zh) * | 2008-12-03 | 2012-07-04 | 中国人民解放军第三军医大学 | 疟原虫环子孢子蛋白抗肿瘤增殖和迁移的新用途 |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
GB2478734A (en) * | 2010-03-15 | 2011-09-21 | Sense Proteomic Ltd | Auto-antibody biomarkers of prostate cancer |
KR101229596B1 (ko) * | 2010-05-13 | 2013-02-04 | 한국외국어대학교 연구산학협력단 | 사람 락토페리신 펩티드의 대장균 발현 플라스미드 및 그 용도 |
EP2753352B2 (en) * | 2010-09-03 | 2022-08-10 | Valneva Austria GmbH | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof |
WO2012117406A2 (en) * | 2011-03-02 | 2012-09-07 | Futuragene Israel Ltd. | Bacterial resistant transgenic plants |
EP3332804A1 (en) | 2011-03-11 | 2018-06-13 | Advaxis, Inc. | Listeria-based adjuvants |
US10258676B2 (en) * | 2011-09-06 | 2019-04-16 | Agency For Science, Technology And Research | Polypeptide vaccine |
US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
EP2758074B1 (en) * | 2011-09-23 | 2020-04-22 | Loma Linda University | Bacterial strains expressing methylase genes and uses thereof |
EP2583975A1 (en) * | 2011-10-21 | 2013-04-24 | Heinrich-Heine-Universität Düsseldorf | Agents and methods for the expression and secretion of peptides and proteins |
WO2013076580A2 (en) * | 2011-11-23 | 2013-05-30 | Bioven 3 Limited | Recombinant proteins and their therapeutic uses |
EP2825195A4 (en) | 2012-03-12 | 2015-10-07 | Advaxis Inc | INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE |
US9499856B2 (en) | 2012-04-02 | 2016-11-22 | The Board Institute, Inc. | DDR2 mutations in squamous cell lung cancer |
IN2014DN09618A (no) * | 2012-05-23 | 2015-07-31 | Us Sec Dep Of Health And Human Services | |
EP2878672A4 (en) * | 2012-07-26 | 2016-02-17 | Nat Cancer Ct | FUSIONSGEN OF CEP55-GEN AND RET-GEN |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
MX2015012461A (es) | 2013-03-15 | 2016-08-08 | Bioven 3 Ltd | Proteinas sintéticas autoensamblables. |
EP2792686A1 (en) | 2013-04-17 | 2014-10-22 | Heinrich-Heine-Universität Düsseldorf | Methods for the expression of peptides and proteins |
LT2988762T (lt) * | 2013-04-25 | 2018-09-25 | Vaximm Ag | Vektoriai, sukonstruoti salmonella pagrindu, skirti vėžio imunoterapijai, nukreiptai į vilmso naviko geną wt1 |
CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
EP3145946B1 (en) * | 2014-05-21 | 2019-08-14 | Universität Basel | Bacteria-based protein delivery |
EP3166637B1 (en) | 2014-07-10 | 2020-01-29 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
WO2016019379A1 (en) * | 2014-08-01 | 2016-02-04 | Northwestern University | Bacterial toxins and uses thereof as ras specific proteases |
MA41217A (fr) * | 2014-12-19 | 2017-10-24 | Advaxis Inc | Polythérapies ayant des souches de listeria recombinées |
CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
EP3288572A4 (en) * | 2015-04-28 | 2018-12-05 | Albert Einstein College of Medicine, Inc. | Treatment of cancer using recall antigens delivered by attenuated bacteria |
JP7266834B2 (ja) | 2015-12-28 | 2023-05-01 | 北海道公立大学法人 札幌医科大学 | 腫瘍抗原ペプチド |
CN105601753A (zh) * | 2016-02-22 | 2016-05-25 | 潍坊医学院 | 结核杆菌噬菌体双组份融合溶菌蛋白及其制备方法和应用 |
CN109803672A (zh) | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 稳定的非蛋白质梭菌毒素组合物 |
EP3515483A4 (en) | 2016-09-21 | 2020-12-16 | The Governors of the University of Alberta | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES |
GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
CN107858430B (zh) * | 2017-11-20 | 2019-01-04 | 武汉迈特维尔生物科技有限公司 | 一种用于诊断预示Her-2过表达型乳腺癌骨转移的基因诊断试剂盒 |
CN109593771B (zh) * | 2018-07-27 | 2022-03-29 | 四川大学华西医院 | 一种人类map2k5第1100位碱基突变基因及其检测试剂盒 |
CN109486832B (zh) * | 2018-12-29 | 2021-11-23 | 中国农业科学院棉花研究所 | 一种创建有限生长株型棉花的方法 |
CN110330548B (zh) * | 2019-06-28 | 2021-03-09 | 哈尔滨医科大学 | 一种抗肿瘤多肽及其在制备抗肿瘤药物中的应用 |
CN110237240A (zh) * | 2019-07-03 | 2019-09-17 | 上海市肺科医院 | 可溶性受体酪氨酸激酶sAxl在治疗结核病中的应用 |
US20220334132A1 (en) * | 2019-08-08 | 2022-10-20 | The Trustees Of Indiana University | Methods for identifying and treating urinary tract infections |
CN114222588A (zh) | 2019-08-12 | 2022-03-22 | 雷杰纳荣制药公司 | 巨噬细胞刺激1受体(mst1r)变体及其用途 |
CN111635937B (zh) * | 2020-06-29 | 2021-10-08 | 江苏省中医院 | Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用 |
JP2023548417A (ja) * | 2020-11-09 | 2023-11-16 | インダストリー、ファウンデーション、オブ、チョンナム、ナショナル、ユニバーシティ | 癌の予防および治療用サルモネラ菌株およびその用途 |
WO2022225267A1 (ko) * | 2021-04-19 | 2022-10-27 | 엠브릭스 주식회사 | 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물 |
CN117805372A (zh) * | 2021-08-30 | 2024-04-02 | 河南中医药大学 | 一种生物标记物在制备检测桥本甲状腺炎脾肾阳虚证的试剂或试剂盒中的应用 |
CN114921546B (zh) * | 2022-05-13 | 2023-02-21 | 核工业总医院 | circHIPK2作为乳腺癌生物标志物的应用 |
GB202209115D0 (en) * | 2022-06-21 | 2022-08-10 | Chain Biotechnology Ltd | Compositions and methods |
WO2024054673A1 (en) * | 2022-09-09 | 2024-03-14 | Texas Tech University System | Listeria monocytogenes as a vector for tumor-specific delivery of chemotherapeutic agents |
CN115976033B (zh) * | 2022-12-14 | 2024-05-17 | 西南大学 | 瓜实蝇tssk1和tssk3基因及其应用 |
KR20240124448A (ko) * | 2023-02-08 | 2024-08-19 | 충남대학교산학협력단 | 종양세포의 괴사를 유발하는 항암 살모넬라 균주 및 이를 포함하는 항암 조성물 |
CN116875520B (zh) * | 2023-07-12 | 2024-06-14 | 吉林农业大学 | 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用 |
CN117511967B (zh) * | 2023-08-31 | 2024-07-02 | 中国科学院华南植物园 | 层出镰刀菌致病力相关基因FpAP1及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02170053A (ja) * | 1988-12-23 | 1990-06-29 | Meiji Seika Kaisha Ltd | 微生物の検出方法及び装置 |
RU2092556C1 (ru) * | 1995-08-29 | 1997-10-10 | Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации | Способ введения чужеродных генов в геномы грамотрицательных микроорганизмов, плазмидный вектор ркс47м для введения чужеродных генов в геномы грамотрицательных микроорганизмов, способ конструирования плазмидного вектора ркс47м |
AU4070097A (en) * | 1996-08-16 | 1998-03-06 | Uab Research Foundation, The | Mucosal immunogens for novel vaccines |
AU7410798A (en) * | 1996-11-29 | 1998-06-22 | General Hospital Corporation, The | Heterologous antigens in live cell V |
US20030235594A1 (en) * | 1999-09-14 | 2003-12-25 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
AU784605B2 (en) * | 1999-10-20 | 2006-05-11 | Johns Hopkins University School Of Medicine, The | Chimeric immunogenic compositions and nucleic acids encoding them |
GB0030067D0 (en) * | 2000-12-11 | 2001-01-24 | Univ Bristol | Therapeutic agent |
RU2216590C1 (ru) * | 2002-02-26 | 2003-11-20 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Рекомбинантный аттенуированный штамм бактерий salmonella typhimurium t10/pkhbc - продуцент корового антигена вируса гепатита в |
DE10208653A1 (de) | 2002-02-28 | 2003-09-18 | Medinnova Ges Med Innovationen | Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren |
-
2006
- 2006-11-13 EP EP06123974A patent/EP1921149A1/en not_active Withdrawn
-
2007
- 2007-11-13 ES ES07822513T patent/ES2347019T3/es active Active
- 2007-11-13 DE DE602007006985T patent/DE602007006985D1/de active Active
- 2007-11-13 WO PCT/EP2007/062237 patent/WO2008058944A1/en active Application Filing
- 2007-11-13 AT AT07822513T patent/ATE469971T1/de active
- 2007-11-13 SI SI200730328T patent/SI2092067T1/sl unknown
- 2007-11-13 PL PL07822513T patent/PL2092067T3/pl unknown
- 2007-11-13 US US11/939,254 patent/US8669091B2/en not_active Expired - Fee Related
- 2007-11-13 KR KR1020097012089A patent/KR101505413B1/ko active IP Right Grant
- 2007-11-13 MX MX2009005038A patent/MX2009005038A/es active IP Right Grant
- 2007-11-13 DK DK07822513.3T patent/DK2092067T3/da active
- 2007-11-13 PT PT07822513T patent/PT2092067E/pt unknown
- 2007-11-13 EP EP07822513A patent/EP2092067B1/en active Active
- 2007-11-13 AU AU2007321266A patent/AU2007321266B2/en not_active Ceased
- 2007-11-13 BR BRPI0719003-4A patent/BRPI0719003A2/pt not_active Application Discontinuation
- 2007-11-13 NZ NZ576947A patent/NZ576947A/en unknown
- 2007-11-13 ME MEP-2010-387A patent/ME01846B/me unknown
- 2007-11-13 CN CN200780044576.6A patent/CN101595219B/zh not_active Expired - Fee Related
- 2007-11-13 AR ARP070105040A patent/AR063795A1/es unknown
- 2007-11-13 UA UAA200906068A patent/UA94974C2/uk unknown
- 2007-11-13 RU RU2009122560/10A patent/RU2447145C2/ru active
- 2007-11-13 TW TW096142857A patent/TWI394834B/zh not_active IP Right Cessation
- 2007-11-13 CA CA002669219A patent/CA2669219A1/en not_active Abandoned
- 2007-11-13 JP JP2009536716A patent/JP5479102B2/ja not_active Expired - Fee Related
- 2007-11-13 RS RSP-2010/0387A patent/RS51416B/en unknown
-
2009
- 2009-05-04 ZA ZA200903022A patent/ZA200903022B/xx unknown
- 2009-05-13 IL IL198736A patent/IL198736A0/en active IP Right Grant
- 2009-06-12 NO NO20092278A patent/NO20092278L/no not_active Application Discontinuation
-
2010
- 2010-01-21 HK HK10100634.0A patent/HK1138314A1/zh not_active IP Right Cessation
- 2010-08-19 CY CY20101100767T patent/CY1111035T1/el unknown
- 2010-08-25 HR HR20100466T patent/HRP20100466T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20092278L (no) | Mikroorganismer som baerere av nukleotid sekvenser kodende for antigener og protein toksiner, fremgangsmate for fremstilling og anvendelser derav | |
Lucas et al. | The tyrosine decarboxylase operon of Lactobacillus brevis IOEB 9809: characterization and conservation in tyramine-producing bacteria | |
Sleytr et al. | Bacterial S-layers | |
Guoyan et al. | Bacillus subtilis spore surface display technology: a review of its development and applications | |
Kitagawa et al. | Biogenesis of Salmonella enterica serovar typhimurium membrane vesicles provoked by induction of PagC | |
JPS58126789A (ja) | レースレオニンの製造法 | |
Harris et al. | Identification of Rhodococcus equi lipids recognized by host cytotoxic T lymphocytes | |
CA2923177A1 (en) | Host cell modification with artificial endosymbionts | |
Hachisuka et al. | Development of a targeted gene disruption system in the poly (ethylene terephthalate)-degrading bacterium Ideonella sakaiensis and its applications to PETase and MHETase genes | |
Barrows et al. | Synchronized swarmers and sticky stalks: Caulobacter crescentus as a model for bacterial cell biology | |
Koopman et al. | Mechanisms and applications of bacterial sporulation and germination in the intestine | |
Bouteiller et al. | Crosstalk between the type VI secretion system and the expression of class IV flagellar genes in the Pseudomonas fluorescens MFE01 strain | |
DE69928556D1 (de) | Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen | |
Preciado-Llanes et al. | Evasion of MAIT cell recognition by the African Salmonella Typhimurium ST313 pathovar that causes invasive disease | |
NZ594029A (en) | Cna_b domain antigens in vaccines against gram positive bacteria | |
Lieber et al. | A multienzyme complex channels substrates and electrons through acetyl-CoA and methane biosynthesis pathways in Methanosarcina | |
Wagner et al. | An integrated strategy for efficient vector construction and multi-gene expression in Plasmodium falciparum | |
Martelet et al. | Porcine dendritic cells as an in vitro model to assess the immunological behaviour of Streptococcus suis subunit vaccine formulations and the polarizing effect of adjuvants | |
Bang et al. | Evidence that expression of the Vibrio vulnificus hemolysin gene is dependent on cyclic AMP and cyclic AMP receptor protein | |
Pan et al. | Complexome of Escherichia coli envelope proteins under normal physiological conditions | |
CN109055398A (zh) | 一种包含密码子优化cfp10基因的结核dna疫苗 | |
Stamm et al. | Epithelial and mesenchymal cells in the bovine colonic mucosa differ in their responsiveness to Escherichia coli Shiga toxin 1 | |
JP5946080B2 (ja) | 藍藻においてプラスチック原料および関連物質を生産する方法 | |
Lee et al. | Overcoming codon-usage bias in heterologous protein expression in Streptococcus gordonii | |
Kong et al. | Porphyromonas gingivalis B cell Antigen Epitope Vaccine, pIRES‐ragB'‐mGITRL, Promoted RagB‐Specific Antibody Production and Tfh Cells Expansion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |